Actively Recruiting
Evaluating Rituximab and CC-99282 as Front-line Therapy for Frail Older Adults with Diffuse Large B-Cell Non-Hodgkin Lymphoma Using Simplified Geriatric Assessment
Led by Fondazione Italiana Linfomi - ETS · Updated on 2026-08-24
47
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of rituximab and golcadomide CC-99282 as a front-line, chemo-free treatment for older frail patients newly diagnosed with Diffuse Large B-Cell Non-Hodgkin Lymphoma DLBCL. This phase II, multicenter study focuses on patients aged 80 years or older who are considered frail based on a simplified geriatric assessment sGA and are not candidates for standard anthracycline-based chemotherapy. The study aims to assess efficacy and safety in this vulnerable population. Participants will receive an induction phase consisting of up to 6 cycles, each lasting 28 days. Cycle 1 includes rituximab intravenously on days 1, 8, and 15, golcadomide orally for days 1 to 14, and dexamethasone orally on days 1, 8, 15, and 22. Cycles 2 through 6 involve rituximab on day 1 and golcadomide orally for days 1 to 14. After induction, patients showing at least a partial response may undergo a consolidation phase starting within 6 to 8 weeks, receiving golcadomide orally for up to 6 more cycles. Involved site radiotherapy is permitted at the end of induction for PET-positive areas and may coincide with consolidation treatment. Throughout the study, patients will undergo response assessments after the 4th and 6th induction cycles and midway through consolidation to evaluate disease progression. Imaging such as PETCT or CT scans will be used for response and sarcopenia assessments. Quality of life will be measured at baseline and at multiple points during and after treatment. Follow-up monitoring will continue for 24 months, with visits every 3 months during the first year and every 6 months during the second year. Patients experiencing disease progression will be followed for survival until study completion. The primary outcome is progression-free survival at 24 months.
CONDITIONS
Brief Title
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Research Team
U
Uffici Studi FIL
U
Uffici Studi FIL
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here